On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (87) Japan Is (Is Not) an Attractive Market Part 2 P. Reed Maurer
June 4, 2007
- Maurer's Healthcare Insight (86)
May 28, 2007
- Maurer's Healthcare Insight (85)
April 16, 2007
- Maurer's Healthcare Insight (84)
March 26, 2007
- Japan's Most Admired Pharma Companies in 2006 P. Reed Maurer
March 12, 2007
- Maurer's Healthcare Insight (83)
February 19, 2007
- 2006: When the Pendulum Swung P. Reed Maurer
January 8, 2007
- Maurer's Healthcare Insight (82)／Questions from the Floor P. Reed Maurer
December 18, 2006
- Maurer's Healthcare Insight (81)
November 20, 2006
- Maurer's Healthcare Insight (80)
October 23, 2006
- Maurer's Healthcare Insight (79) Back from the Saddle P. Reed Maurer
September 25, 2006
- Maurer's Healthcare Insight (78) Infinite Value of a Good Boss P. Reed Maurer
August 28, 2006
- Maurer's Healthcare Insight (77)
July 24, 2006
- Maurer's Healthcare Insight (76)
June 26, 2006
- Maurer's Healthcare Insight (75)
May 29, 2006
- Maurer's Healthcare Insight (74)
April 10, 2006
- Maurer's Healthcare Insight (73)
March 13, 2006
- Maurer's Healthcare Insight (71)
December 19, 2005
- Maurer's Healthcare Insight (70)
November 28, 2005
- Maurer's Healthcare Insight(69)
November 14, 2005
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…